Drug Trial Radar · NCT06533540
Safety Study of TPX-121 on Nasolabial Folds
Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Mar 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Tego Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nasolabial folds augmentation is possible through dermal filler and botulinum toxin, however, safety issues are existed as well as efficacy. Therefore, there is a need for a safer procedure for nasolabial folds correction. This study (Project No. TPX-121) assesses the safety of allogeneic fibroblasts (TPX-115) on nasolabial folds. The safety endpoint is dose-limiting toxicity (DLT). In addition, exploratory endpoints are the improvement of nasolabial folds in Wrinkle Severity Rating Scale (WSRS) at week 4 and 12, change in WSRS and Wrinkle Severity Scale (WSS) at week 4 and 12, and overall appearance improvement rate in Global Aesthetic Improvement Scale (GAIS) at week 4 and 12.
Conditions
- Nasolabial Fold, Hypoplastic
Interventions
TPX-115(allogeneic fibroblasts)Biological
Intradermal injection of TPX-115(allogeneic fibroblasts)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyungpook National University, School of Medicine
Daegu, Jung-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.